抗凋亡蛋白表达与晚期乳腺癌紫杉醇化疗敏感性的关系

Relationship between expression of anti-apoptotic protein survivin in breast cancer tissues and chemosensitivity of pacilitaxel

目的:探讨抗凋亡蛋白Survivin在乳腺癌组织中的表达及其与晚期乳腺癌紫杉醇化疗敏感性的关系。方法:应用免疫组化方法,对40例应用紫杉醇化疗的乳腺癌患者癌组织中Survivin表达水平进行检测,分析其与紫杉醇化疗敏感性的关系。结果:乳腺癌患者Survivin表达阳性率为60·0%(24/40);紫杉醇化疗后,有效组(CR+PR)患者Survivin阳性率为40·9%(9/22),无效组(NC+PD)患者Survivin阳性率为83·3%(15/18),两者之间差异有统计学意义,χ2=7·424,P=0·006。结论:Survivin表达水平与乳腺癌对紫杉醇化疗敏感性呈负相关,Survivin可能作为一项筛选乳腺癌化疗药物、指导制定合理治疗方案的新指标。

OBJECTIVE： To study the correlation between the chemosensitivity of pacilitaxel and the expression levels of anti-apoptotic protein survivin in breast cancer tissues. METHODS： The expressions of survivin in 40 patients with breast cancer which were treated with pacilitaxel chemotherapy were detected by the immunohistochemical staining, and the results were analysed for the correlation to chemosensitivity of pacilitaxel. RESULTS： The positive expression rate of survivin was 60. 0% （24/40） in breast cancer tissues. After treatment by pacilitaxel, the expression rates of survivin were 40. 9% （9/22） in remission group, 83.3%（15/18） in stable and progressive group, respectively, χ^2 = 7. 424, P = 0. 006. There was a significant difference in the expressions of survivin between remission and progressive groups. CONCLUSIONS： The survivin expression is negatively related to the sensitivity of breast cancer cells to pacilitaxel. The survivin might be a valuable new marker for selecting chemical drugs, guiding the plan of rational therapeutic scheme in human breast cancer.